Introduction
factors are involved not only in disease susceptibility but also in the chronicity, severity and the patient's response to therapy. Currently, there is no cure for RA and treatment is directed at symptom reduction and minimisation of disease activity and progression 1 . Even though the pathogenesis of RA is not fully understood, it is commonly accepted that the pro-inflammatory cytokine tumour necrosis factor (TNF) has a key role in the inflammatory process. TNF neutralising approaches have proven highly effective in the treatment of RA and other autoimmune diseases. However, long-lasting response only occurs in approximately 70% of the patients and the causes for non-response are unknown 1 . Inefficacy of anti-TNF therapy in a considerable percentage of patients, together with reported adverse events and the high costs of anti-TNF blocking agents have driven the search for genetic markers capable of predicting treatment response.
approach is a hypothesis-driven approach in which DNA polymorphisms in candidate genes are investigated for their effect on treatment response. The second approach is a so-called nonhypothesis-driven approach in which genome-wide techniques are used to identify genetic markers for treat-ment response. Using these genome-wide techniques, it is possible to investigate hundreds of thousands of genetic variants in one single experiment.
This critical review provides an overview of the current literature concerning DNA polymorphisms and their role in anti-TNF therapy response in patients with RA. Results obtained using either the hypothesis-driven approach or the non-hypothesisdriven approach, are discussed in this review.
Discussion
The author has referenced some of its own studies in this review. These referenced studies have been conducted in accordance with the Declaration of Helsinki (1964) and the protocols of these studies have been approved by the relevant ethics committees related to the institution in which they were performed. All human subjects, in these referenced studies, gave informed consent to participate in these studies.
Candidate gene studies ( hypothesis-driven approach)
The focus of anti-TNF pharmacogenetic studies has been mainly
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Genetic variation is partly responsible for the differences in therapy response and adverse events observed in RA patients. Pharmacogenetic research focuses on identifying the DNA sequence variants that influence drug response and/or toxicities. In this way, researchers hope to develop tools to predict treatment response prior to treatment start and determine the optimal treatment regimen for an individual patient. Much effort has been put into the identification of genetic markers predicting anti-TNF treatment outcome. In general, two approaches are used to identify these genetic markers. The first Rheumatoid arthritis (RA) is a common chronic inflammatory disease mainly affecting the synovial joints. It is a multifactorial disorder in which both genetic and non-genetic functional polymorphisms located in candidate genes . These candidate genes are involved in the pathogenesis of RA, implicated in the mechanisms of action of TNF-α or involved in the breakdown and clearance of anti-TNF agents. Evidence from several studies suggests that genes involved in RA disease severity are also good candidates for influencing treatment response 1, 19 . This is especially the case for TNF-blocking therapy since this therapy interferes with the proinflammatory TNF pathway. Therefore, several studies have selected genetic variants in RA susceptibility genes as candidates for anti-TNF non-response 17, 19 . Table 1 provides an overview of the studies investigating genetic variants in candidate genes for anti-TNF non-response. The large number of studies does not make it possible to discuss each individual study in detail, in this review. Nevertheless, from these studies, it can be concluded that although no genetic marker has been identified yet, it can still predict anti-TNF treatment outcomes with high sensitivity and specificity. The literature on these candidate gene studies is plagued by contradictory results. This can be related to the use of different ethnic groups or different outcome definitions, but most often it seems to be attributed to the low statistical power of the studies since the investigated patient cohorts are generally very small, 1, [4] [5] [6] 8, 12, 14, 15, 22, 23 . As a result, studies are unable to detect differences between responders and nonresponders to anti-TNF therapy. On the other hand, small sample sizes may also lead to overestimation of the strength of a certain association, for instance, a positive association that appears by chance or because of sampling biases. Therefore, replication of association findings by different researchers and across diverse samples is essential to draw definitive conclusions about whether an association really exists. Another way to draw more definite conclusions concerning the association of a genetic variant with anti-TNF response is by combining studies in a meta-analysis. A meta-analysis is a statistical procedure integrating results from several studies to produce a single estimate with enhanced precision. Therefore, a meta-analysis of all published data concerning a specific polymorphism could help to draw more definitive conclusions on the role of polymorphisms in predicting anti-TNF treatment outcome in patients with RA. This is shown in the metaanalysis conducted by Zeng et al. 24 , in which 15 studies were included that investigated the TNFA (TNF-α) promoter-308 G/A polymorphism in relation to responsiveness to anti-TNF therapy in RA patients. Although individual studies investigating this polymorphism reported contradictory results 1, 10, 25 , the researchers concluded that RA patients with the TNF-α promoter-308 G allele responded better to TNF-α antagonist treatment.
In the case that a (supposed) functional polymorphism is associated with therapy outcome, it is still possible that the effect is not caused by the polymorphism itself but by another polymorphism, which is in linkage disequilibrium (LD) with the former. LD describes a situation in which some combinations of alleles the HapMap consortium. In the last few years, LD-based analysis has been increasingly applied in pharmacogenetic research.
Although the hypothesis-based candidate gene approach is appealing, it does not account for the potential role of genes other than the obvious candidates, including the genes of unknown function. Therefore, a candidate-driven approach is limited by the existing knowledge about disease aetiology and modes of action of the therapeutic agent under study. An approach to partially solve this problem is the so-called 'candidate pathway' approach. This method takes into account complete downstream and interacting signalling pathways of a candidate gene. Pathways of genes harbouring allelic variants may have more impact on drug response than one polymorphism in an individual gene, as several polymorphisms in networks of genes may interact. One study that used this 'candidate pathway' approach investigated genes located in the TNF receptor superfamily member 1B signalling pathway. They identified two SNPs located in the genes MAP3K1 (mitogen-activated protein kinase kinase kinase 1) and MAP3K14 (mitogen-activated protein kinase kinase kinase 14) to be associated with anti-TNF treatment response 26 .
Genome wide association studies (non-hypothesis-driven approach)
Since the present knowledge on the aetiology and course of RA and the modes of action of new therapeutics like anti-TNF treatment is still limited, more non-hypothesisdriven approaches ('fishing expeditions') also seem warranted. The best example of the latter are studies aimed to search for genes involved in complex traits in a genome-wide fashion, like a genome-wide association study (GWAS) 27 . This technique makes it feasible to analyse hundreds of thousands of SNPs in one single experiment. Association is detected via a surrogate marker (tag SNP) in LD with the true causal variant (which can be an SNP, copy number variant or repeat-type polymorphism). A GWAS has the advantage of investigating many genes at the same time including those genes whose function, in relation to the studied trait, is not yet fully understood or recognised. Limitations of the GWAS are the (still) relatively high costs and the large samples required to account for multiple testing in combination with small effect sizes of individual variants. A less expensive way to increase power is a meta-analysis in which relevant studies are combined.
So far, three GWASs for identifying genetic markers for anti-TNF response have been performed [28] [29] [30] . Liu et al. 28 identified SNPs located in the genes MAFB (v-maf musculoaponeuroticfibrosarcoma oncogene homolog B), IFNk (interferon kappa) and PON1 (paraoxonase I) as weak markers for anti-TNF response. However, the number of patients analysed was small (n = 89) and no replication cohort was included. A more comprehensive, three-stage GWAS approach was used by Plant et al. 29 . First, a GWAS was conducted using a cohort of 566 anti-TNF-treated RA patients. Next, genetic markers identified in this first analysis to be associated with anti-TNF response, were replicated in two independent patient cohorts consisting of 379 (stage 2) and 341 (stage 3) patients, respectively. They reported the genes EYA4 (eyes absent homolog) and PDZD2 (PDZ domain-containing protein 2) to be associated with anti-TNF response. Nevertheless, a more recent GWAS, which also used such a comprehensive three-stage study design, was not able to replicate these associations. In this study, an initial GWAS was performed which included 984 RA patients treated with anti-TNF medication (stage 1). Subsequent follow-up of the most significant signals was performed in two replication cohorts (stage 2 [n = 954] and stage 3 [n = 867]). This study did not identify a novel genetic marker for anti-TNF response30.
Many genetic variants are likely to have a role in therapy response and the contribution of each single polymorphism is probably modest and therefore difficult to identify. For these reasons, it is of utmost importance for candidate gene-based studies as well as GWASs to investigate very large sample sizes and ensure that those patient cohorts are well characterised for demographics, disease characteristics and therapy response at baseline and during follow-up. Large samples increase the study power and a thorough patient characterisation allows better patient stratification, increasing the chance of identifying true associations.
Nonetheless, the candidate gene and the GWAS are only the first steps in identifying genetic markers/ genes for anti-TNF response. To verify results from GWAS trials, studies should be replicated in additional, independent patient samples to guarantee their validity and generalisability and should be followed-up by more focused studies searching for causal variants in the region of interest. The identification of causal variants is of particular interest to gain more insight into the mechanisms underlying anti-TNF treatment response.
Gene expression studies and combination with other 'omics' strategies (non-hypothesis-driven approach)
Another non-hypothesis-driven approach to search for genes involved in anti-TNF treatment outcome is the use of genome-wide gene expression studies. During the last decade, gene expression profiling has emerged as a key tool in the study of various complex diseases and traits. treatment in patients with RA 31, 32 . Quite a few of the identified genes did not only have a (potential) role in anti-TNF response but are also candidate genes for RA severity, backing up the hypothesis that (a subset of) the same genes are involved in both disease severity and anti-TNF treatment.
Specifically, in microarray experiments, there is an increased chance of false positives because of the multiplicity problem: thousands of hypotheses (in this case, genes) are tested simultaneously for their association with anti-TNF response. Therefore, there is a need to correct for multiple testing when assessing the statistical significance of findings. Due to the high costs and the time-consuming procedure to collect sufficient samples in a standardised manner, microarray experiments are often underpowered. When multiple-testing correction is applied in these underpowered studies, not a single gene or polymorphism may be identified as true positive. However, this does not mean that the results obtained from these studies are not informative, and may still be considered as a matter of debate. The biological functions and mechanisms underlying the identified genes and polymorphisms are often involved in the mechanisms underlying the investigated complex trait 33 . Therefore, in the last few years, a shift has been observed in the interpretation of results from microarray experiments. The focus is no longer on multiple-testing correction but on validation of the exploratory results in independent patient cohorts.
In addition to gene expression profiling, studies on protein profilesthe so-called proteomics studiesare also of interest. For example, a sustained increase of soluble CD30 levels has been recently reported to be associated with non-response to anti-TNF therapy 34 . Integration of the results from the above described techniques (candidate gene analysis, GWAS and expression profiling) with those of an analysis at the level of the proteome (two dimensional gel electrophoresis, surface-enhanced laser desorption/ionisation-time of flight, clinical markers (rheumatoid factor positivity, C-reactive protein and anti-cyclic citrullinated peptide antibody) and important environmental factors), is probably the most powerful way to identify markers for anti-TNF therapy outcome.
Towards personalised medicine?
What has genetics taught us so far about differences in anti-TNF therapy response? Although progress has been made in the search for genetic polymorphisms related to anti-TNF response, it has to be concluded that no marker with high sensitivity and specificity was identified so far. All data generated suggests that anti-TNF non-response is a more complex phenomenon than what was anticipated several years ago. It is unlikely that a single genetic variant will predict anti-TNF treatment outcome. It is more likely that a set of genes and genetic variants together will be capable of predicting anti-TNF treatment response. The genetic variants involved in non-response to anti-TNF therapy probably have smaller effect sizes than the effect sizes seen in pharmacogenetic tests that are used in daily practice. Most drug effects are polygenic, meaning that the drug-processing pathway (metabolism, transportation and target interaction) displays genetic variation between patients. Clear-cut frequency distributions, as observed for tests used in daily practice, would be replaced by multiple overlapping distributions, thereby obscuring the relationship between the drug and target. To identify these genetic variants, it is of utmost importance to investigate large, preferably homogeneous patient cohorts. Consortiums with access to these large, well characterised populations are needed to tackle the problem of anti-TNF nonresponse.
Seen these small effect sizes, it is important to consider additive effects as well as interactions between genetic polymorphisms in pharmacogenetic studies. Besides, these gene-gene interactions, individual disease courses and treatment responses, are also influenced by gene-environment interactions. For example, a prominent geneenvironment interaction was identified between smoking and the HLA-DRB1 shared epitope alleles 35 .
Since gene-gene and gene-environment interactions are also involved in therapy response, the main goal in pharmacogenomic research is to incorporate genomic information with demographic and environmental covariates to obtain a genotype-to-phenotype map, which can be used to personalise a treatment regimen for a disease. Such a multivariate analysis for therapy response in RA is elegantly shown in the study of Wessels et al 36 . In this study, a clinical pharmacogenetic model was developed which can be used to predict methotrexate (MTX) response in patients with RA. This model included four polymorphisms located in MTX response candidate genes (AMPD1, ATIC, ITPA and MTHFD1) together with sex, rheumatoid factor, smoking status and the disease activity score. Using this model, 60% of the patients were categorised as either a MTX responder or non-responder, whereas only 32% of the patients were categorised when a non-genetic model was applied. From this comparison, they concluded that pharmacogenetics is of great value for predicting response to MTX. It would also be of great value to develop such a pharmacogenetic model for anti-TNF treatment.
Potentially important phenotypic and environmental factors that need to be taken into account regarding Licensee anti-TNF response are the formation of antibodies directed against anti-TNF agents and smoking. Some studies suggest that both may be associated with non-response to anti-TNF agents 37 . The process of antibody formation against biological agents is increasingly suggested to be one of the mechanisms related to drug failure. Several patients who fail to respond to the first anti-TNF agent, benefit from a switch to a second anti-TNF agent. This suggests a mechanism of neutralising antibodies directed against the firstused anti-TNF agent. Indeed, studies showed a correlation between clinical response and the formation of anti-TNF antibodies 38 . When such pharmacogenetic models are developed for several RA treatment strategies, it will increase the possibility of identifying the best treatment regimen for each individual patient. This will result in a more aggressive and targeted treatment soon after diagnosis. However, it is methodologically demanding to investigate the relationship between several (genetic and environmental) factors as these factors may be interrelated in varying degrees between RA patients. Therefore, completeness of information and non-biased recruitment of the study cohorts is crucial for the reliability of results.
Future research perspectives
Pharmacogenetic studies reported so far are only beginning to unravel the genetic complexity underlying the mechanisms of anti-TNF response. In the next few years, the focus will shift from the hypothesis-driven pharmacogenomic approaches towards the non-hypothesis-driven approaches in which the entire genome, transcriptome and proteome is screened for relevant variation associated with response to anti-TNF treatment. In addition, the technique of next generation sequencing (or re-sequencing) is very promising. This technique offers high throughput sequencing of the entire genome for relatively low costs, thereby providing information on literally every nucleotide in the genome. Within three to five years, this technique will be standard for genomic screening of large patient cohorts. Genomic data from such screens (GWAS or next-generation sequencing) will be combined with data obtained from transcriptomic and proteomic screens using sophisticated statistical methods for the identification of markers that can predict treatment outcome in a substantial part of the patients. However, these large genome-wide screens on the DNA, RNA and protein levels will only be successful if they are applied on large, well-characterised cohorts. Therefore, multicentre pharmacogenomic collaborations should concentrate on collecting these well-defined patient cohorts, which provide sufficient statistical power to detect the supposedly small genetic effects associated with treatment outcome and/or disease course.
Conclusion
Although progress has been made in the search for genetic polymorphisms related to anti TNF response, it has to be concluded that no marker with high sensitivity and specificity has been identified so far. Pharmacogenetic testing is yet in its infant stages for the study of complex diseases. However, the proposed approaches will most certainly lead to the identification of markers for anti-TNF therapy response, resulting in a more personalised treatment strategy. The application of 'tailor-made' personalised medicine in the daily clinic will be of great benefit to the individual patient.
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